IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-16. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Due to his high popularity, Duterte remained influential before the national elections as several presidential candidates were open to his endorsement. As the Cusi faction was left without a standard bearer following Go's withdrawal, allies of Duterte endorsed different candidates. The Cusi faction eventually endorsed presidential candidate Marcos and some officials called for Duterte to do the same. Stressing he would remain neutral, Duterte refused to heed their calls and insisted on endorsing only Sara as vice president and 17 senatorial candidates. Additionally, in an effort to protect their integrity, Duterte barred his Cabinet members from campaigning for any candidate. Despite non-endorsement, Duterte hinted on the next president's preferred qualities: decisive, compassionate, a good judge of a person, and preferably, a lawyer; this led a PDP-Laban official to believe Duterte gave a "virtual endorsement" for Vice President Leni Robredo, who was Marcos' chief rival in the presidential race. In March 2022, Go said Duterte briefly met with Marcos and gave him advice on the presidency, but could not say whether Duterte gave Marcos an endorsement.
== Office closures == In August 2026, TikTok announced plans to close its Nashville, Tennessee, office, with the closure scheduled for October 5, 2026. The decision will affect approximately 250 employees, according to a notice filed with the Tennessee Department of Labor and Workforce Development. The Nashville location had included members of TikTok's content moderation operations. The company said the closure was intended to reorganize its U.S. operations and bring teams into closer alignment with its long-term plans.
==== Hypoxia/anoxia intolerance ==== Research on intolerant ectotherms is more limited than on tolerant ectotherms and intolerant endotherms, but it is shown that anoxia/hypoxia intolerance is different in terms for how long the intolerant survive as opposed to the tolerant between endotherms and ectotherms. While intolerant endotherms only last minutes, intolerant ectotherms can last hours, such as subtidal scallops (Argopecten irradians). This difference in intolerance could be due to a couple of different factors. One advantage is that the ectothermic inner mitochondrial membrane is less leaky, so less protons will leak through the inner membrane due to differences in the phospholipid bilayer composition. Another advantage ectotherms tend to have in this category is an ability for their mitochondria to properly function in a wide range of temperatures, such as the western fence lizard (Sceloporus occidentalis). While western fence lizards are not considered a hypoxia-tolerant animal, they still showed less temperature sensitivity in their mitochondria than mice mitochondria.
Public awareness and advocacy play crucial roles in driving the research agenda and policy development for CEC, highlighting the need for updated manufacturing practices and developing more remediation and detection methods.
The overall pulp cavity may become smaller by the addition of secondary or tertiary dentin and cause pulp recession. The lack of sensitivity associated with older teeth is due to receded pulp horns, pulp fibrosis, the addition of dentin, or all these changes. Restorative treatment can be performed without local anaesthesia on older dentitions.
Sources: en.wikipedia.org
=== Anti-competitive practices === AbbVie has been accused of using anti-competitive patent thickets to prevent potentially cheaper biosimilars from entering the market. AbbVie and Alvotech, filed lawsuits against each other regarding a Humira biosimilar introduced by Alvotech. The lawsuits were settled out of court in 2022. Forest Laboratories, a subsidiary of AbbVie, was accused of using unlawful deals to prevent generic versions of its Alzheimer's disease drug, Namenda, from entering the market. In 2018, AbbVie agreed to pay $25 million to resolve allegations that it used kickback schemes to promote its cholesterol drug TriCor (fenofibrate). In 2020, AbbVie agreed to pay $24 million to resolve allegations that it used kickback schemes to promote Humira using "nurse ambassadors". A report from the House Oversight and Reform Committee found that "AbbVie pursued a variety of tactics to increase drug sales while raising prices for Americans, including exploiting the patent system to extend its market monopoly, abusing orphan drug protections to further block competition, and engaging in anticompetitive pricing practices". Pursuant to the Inflation Reduction Act, the price of Imbruvica was reduced by 38%, to $9,319 per month, effective in 2026.
== Selection and training == From early 1978 to 1980, support, training, and selection consisted of 3 phases, culminating latterly in 6 months/24 weeks training, with the first phase lasting as long as 11 weeks (the RLI's first phase was 6 weeks). Emphasis in selection depended on extreme physical fitness and aggression (running at an excess of 120 kilometres per week), mental strength in decision making and problem solving under extreme duress. The selection course consisted of a junior leader assessment in all areas concerning leadership. All Counter Operations Insurgency (COIN) battle drills were held in battle camps at Concession and Shamva. The pass rate among recruits amounted to only 30%. On passing out, recruits were deployed to one of 13 and latterly 14 troops (Troop company strength being 120 men; Mantle Mounted and November Troop being new additions in 1981). The Support Unit supported the Police in rural problem areas (latterly dissidents), as well as in urban emergencies. In November 1980, during the Entumbani I uprising, two sections of 60 men each from 5 Support Unit Troops (Mantle Echo, Mantle Charlie, Mantle Juliet, Mantle Hotel, Mantle Lima, 300 men in all), travelled from all over Zimbabwe to reach Bulawayo in 11 hours. Due to the Support Unit Troops being independent with their own vehicles, stores, ammunition, medical supplies, tents etc., they could deploy anywhere at a moment's notice all over Zimbabwe.
the Emil Fischer Medal of the Society of German Chemists (1922), the Cannizaro Prize of the Royal Academy of Science in Rome (1938), the Copernicus Prize of the University of Konigsberg (1941), the Gothenius Medal of the Akademie der Naturforscher (1943), the Max Planck Medal of the German Physical Society, with Lise Meitner (1949), the Goethe Medal of the city of Frankfurt-on-the-Main (1949), the Golden Paracelsus Medal of the Swiss Chemical Society (1953), the Faraday Lectureship Prize with Medal from the Royal Society of Chemistry (1956), the Grotius Medal of the Hugo Grotius Foundation (1956), the Wilhelm Exner Medal of the Austrian Industry Association (1958), the Helmholtz Medal of the Berlin-Brandenburg Academy of Sciences and Humanities (1959), and the Harnack medal in Gold from the Max Planck Society (1959).
==== Ugi Condensation ==== An Ugi condensation reaction can also be used at the carboxyl group using diamine, formaldehyde, and cyclohexyl isocyanide at a low pH. This reaction produces diamide linkages between the polysaccharide chains.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.